Neuphoria Therapeutics Inc.
NEUP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001191070
No open-market purchases or sales by Neuphoria Therapeutics Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $8.71M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Neuphoria Therapeutics Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 9 | 15 | +6 |
| Shares | 178.0K | 195.3K | +17.4K (+9.8%) |
| Value | $1.26M | $2.30M | +$1.04M (+82.3%) |
New holders (9)
Institutions that held Neuphoria Therapeutics Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Diadema Partners LP | 21,452 | $252.9K | 0.18% |
| Vanguard Group Inc | 20,950 | $247.0K | 0.00% |
| Millennium Management LLC | 18,329 | $216.1K | 0.00% |
| Jane Street Group, LLC | 15,669 | $184.7K | 0.00% |
| Geode Capital Management, LLC | 12,978 | $153.0K | 0.00% |
| Persistent Asset Partners Ltd | 4,908 | $57.9K | 0.04% |
| UBS Group AG | 2,168 | $25.6K | 0.00% |
| Tower Research Capital LLC (TRC) | 410 | $4.83K | 0.00% |
| FMR LLC | 2 | $24 | 0.00% |
Sold out (3)
Institutions that held Neuphoria Therapeutics Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Lynx1 Capital Management LP | 45,806 | $325.2K |
| Citadel Advisors LLC | 14,606 | $103.7K |
| Cyndeo Wealth Partners, LLC | 10,000 | $71.0K |